TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St to open higher on oil retreat, tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
TherapeuticsMD (TXMD) Misses Q4 EPS by 5c
March 2, 2021 7:12 AM ESTTherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.15), $0.05 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $22.6 million versus the consensus estimate of $21.89 million.
For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.
... More